MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-28-2026
Incyte Corporation Net Debt 2011-2026 | INCY
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Incyte Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.06 B | -1.65 B | -3.18 B | -2.91 B | -2.02 B | - | -1.8 B | -872 M | -876 M | 651 M | 718 M | 237 M | 228 M | 111 M | 341 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 718 M | -3.18 B | -1.01 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.88 | -1.69 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | France |
 |
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.1 | 1.23 % | $ 438 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.45 | 1.13 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | USA |
 |
Cerus Corporation
CERS
|
-6.9 M | $ 2.03 | 5.73 % | $ 387 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-5.43 M | $ 13.64 | 9.82 % | $ 1.81 B |  Australia |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
BioNTech SE
BNTX
|
-973 M | $ 103.45 | 1.85 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.44 | -3.36 % | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
-87 M | $ 3.0 | 6.38 % | $ 266 M | USA |
 |
Edesa Biotech
EDSA
|
-7.74 M | $ 18.27 | 14.94 % | $ 58.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.19 | 6.69 % | $ 5.25 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
10.2 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-9.94 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |